General conditions at baseline and after the 12-week treatment
TG
Compared those during screening period, HbA1c and FBG in the three groups were significantly improved after 12 weeks of treatment (P<0.05), but weight changes were not statistically significant (P>0.05). Compared with those during the lead-in period, the insulin doses in the Ins+Met and Ins+SZ-A groups decreased after 12 weeks of treatment (P<0.05). After 12-week treatment, the HbA1c, FBG and insulin dosages of Ins+Met and Ins+SZ-A groups were lower than those of the Ins group (P<0.05), and there was no statistically significant difference in weight between the three groups (P>0.05; General conditions at baseline and after 12-week treatment.*represents P < 0.05 (comparison between baseline and after 12-week treatment in each group).

Compared with those in the screening period, the TG and HDL indicators of the Ins+Met group (P<0.05), the TG, HDL and LDL levels of the Ins+SZ-A group (P<0.05), and the LDL levels of the Ins group (P<0.05) all improved after the 12 weeks of treatment, there were no significant differences in the other indicators (P<0.05). After 12 weeks treatment, the improvement in TG and HDL levels seen in the Ins+Met and Ins+SZ-A groups was greater than those in the Ins group (P<0.05). There were no significant differences in the other indicators (P>0.05; 